1311 related articles for article (PubMed ID: 16544145)
21. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
22. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
23. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
24. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
25. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.
Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY
Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355
[TBL] [Abstract][Full Text] [Related]
26. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
27. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration.
Lopez RA; Goodman AB; Rhodes M; Blomberg JA; Heller J
Anticancer Drugs; 2007 Sep; 18(8):933-9. PubMed ID: 17667599
[TBL] [Abstract][Full Text] [Related]
28. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
29. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
30. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
31. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
Qi X; Chang Z; Song J; Gao G; Shen Z
Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
Xu D; Lu Q; Hu X
Cancer Lett; 2006 Nov; 243(2):274-80. PubMed ID: 16406853
[TBL] [Abstract][Full Text] [Related]
35. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
36. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
37. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
Mi Q; Cui B; Silva GL; Lantvit D; Lim E; Chai H; You M; Hollingshead MG; Mayo JG; Kinghorn AD; Pezzuto JM
Cancer Res; 2001 May; 61(10):4030-7. PubMed ID: 11358822
[TBL] [Abstract][Full Text] [Related]
38. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
40. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
